Nutrilite Memory Builder on the Improvement of Cognitive Function

The Effect of Nutrilite Memory Builder on the Improvement of Cognitive Function: A Randomized Controlled Trial(RCT)

Its a randomized controlled trial, to evaluate the effect of NUTRILITE Memory Builder on the improvement of cognitive function in middle-aged and elderly people.

The study center will recruit 100 male or female subjects aged 40-75 years as needed. Enrolled subjects will be divided into 2 groups, with 50 subjects in each group.

Study subjects will be administrated with either the Amway product or a placebo for three months (12 weeks). At least 42 subjects in each group (84 in total) are required to complete the study.

Inclusion Criteria:

• Males or females, 40-75 years old (with age groups of 40-60 years and 61-75 years as close as possible to a 1:1 ratio);
• Healthy subjects with no underlying diseases and no drug treatment at the time of screening;
• Meet the requirements of MMSE scores of 24-29;
• Be willing to comply with all study requirements and procedures;
• Agree to sign the informed consent form.

Exclusion Criteria:

• Participated in similar clinical trials in the last 6 months;
• Have mental illness or disorders of consciousness and behavior;
• Have severe chronic diseases and are currently under treatment with drugs;
• Have taken drugs that can affect cognitive function (such as first-generation antihistamines, benzodiazepines, sedatives, opiates, stabilizers, antidepressants, cholinergic drugs, anticholinergic drugs, prescription anti-inflammatory drugs) and any other regularly influential agents.
• Had flu/virus symptoms within 3 months before screening;
• Received within 3 months before screening or currently receiving medical or nutritional treatments, including protein supplementation or substances that provide exercise capacity;
• Had weight gain or weight loss of more than 5kg within 3 months before screening;
• Have a history of hospitalization within 3 months before screening;
• Have any of the following medical history or have been clinically diagnosed with any of the following diseases: obvious gastrointestinal disorders; liver, kidney, endocrine, blood, respiratory and cardiovascular diseases. These may affect the assessment of product efficacies.
• Have high daily alcohol consumption, i.e. more than 14 bottles of beer (350 ml/bottle) or wine (180 ml/bottle) per week;
• The PI believes that the subjects cannot fully cooperate with the trial arrangement.